Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer

A Proportional Hazards Model for the Subdistribution of a Competing Risk

Jason P. Fine · Journal of the American Statistical Association · 1999 · 13.6K citations

Public Health, Biostatistics, Cost-effectiveness Analysis +15

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

Sarah C. Darby, Marianne Ewertz, Paul McGale et al. · New England Journal of Medicine · 2013 · 4K citations · Full text

Medicine, Cardiology, Oncology +17

Tutorial in biostatistics: competing risks and multi‐state models

Hein Putter, Marta Fiocco, Ronald B. Geskus · Statistics in Medicine · 2006 · 2.4K citations

Public Health, Biostatistics, Epidemiologic Methods +9

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

Stephen G. Chun, Chen Hu, Hak Choy et al. · Journal of Clinical Oncology · 2016 · 748 citations · Full text

Medicine, Oncology, Radiation Oncology +17